AU2003203529A1 - Selection of markers - Google Patents

Selection of markers Download PDF

Info

Publication number
AU2003203529A1
AU2003203529A1 AU2003203529A AU2003203529A AU2003203529A1 AU 2003203529 A1 AU2003203529 A1 AU 2003203529A1 AU 2003203529 A AU2003203529 A AU 2003203529A AU 2003203529 A AU2003203529 A AU 2003203529A AU 2003203529 A1 AU2003203529 A1 AU 2003203529A1
Authority
AU
Australia
Prior art keywords
dna
human
portfolio
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003203529A
Other languages
English (en)
Inventor
Tim Jatkoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Clinical Diagnostics Inc
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of AU2003203529A1 publication Critical patent/AU2003203529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)
  • Peptides Or Proteins (AREA)
AU2003203529A 2002-03-29 2003-03-28 Selection of markers Abandoned AU2003203529A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36879002P 2002-03-29 2002-03-29
US60/368790 2002-03-29

Publications (1)

Publication Number Publication Date
AU2003203529A1 true AU2003203529A1 (en) 2003-10-23

Family

ID=27805329

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003203529A Abandoned AU2003203529A1 (en) 2002-03-29 2003-03-28 Selection of markers

Country Status (10)

Country Link
US (2) US20030194734A1 (https=)
EP (1) EP1349104A3 (https=)
JP (1) JP2004163388A (https=)
KR (1) KR20030078803A (https=)
CN (1) CN1495272A (https=)
AR (1) AR039212A1 (https=)
AU (1) AU2003203529A1 (https=)
BR (1) BR0303080A (https=)
CA (1) CA2422309A1 (https=)
MX (1) MXPA03002865A (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2006013862A1 (ja) * 2004-08-02 2006-02-09 Banyu Pharmaceutical Co., Ltd. Ｃｄｋ４阻害剤に対する薬剤感受性の予測方法
CA2589782A1 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
KR100690250B1 (ko) * 2005-01-31 2007-03-12 디지탈 지노믹스(주) 폐암 진단용 마커
JP2008528024A (ja) * 2005-01-31 2008-07-31 ディジタルジェノミクスインコーポレーション 肺癌診断用マーカー遺伝子
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
IL177006A0 (en) 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
US20070207467A1 (en) 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
CA2644586A1 (en) * 2006-03-03 2008-04-17 Veridex Llc Molecular assay to predict recurrence of duke's b colon cancer
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP1939805A1 (en) * 2006-12-22 2008-07-02 X-Shares Advisors LLC Portfolio selection for custom indices of public securities based on state of domicile of issuing company
EP2413142B1 (en) 2007-02-27 2013-06-05 Nuclea Biomarkers LLC Method for predicting the response of NSCLC-patients to treatment by an EGFR-TK inhibitor
CA2712773A1 (en) * 2008-01-22 2009-07-30 Veridex, Llc Molecular staging of stage ii and iii colon cancer and prognosis
EP2271775A4 (en) 2008-04-08 2011-09-07 Nuclea Biomarkers Llc BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
WO2010124372A1 (en) 2009-04-29 2010-11-04 Genomedx Biosciences, Inc. Systems and methods for expression-based classification of thyroid tissue
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2005927A1 (en) * 1988-12-21 1990-06-21 Chander Bahl Method of preparing nucleotide probes using a bridging complement
US6350576B1 (en) * 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
US6275814B1 (en) * 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) * 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6401043B1 (en) * 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
US6714925B1 (en) * 1999-05-01 2004-03-30 Barnhill Technologies, Llc System for identifying patterns in biological data using a distributed network
US6175824B1 (en) * 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
IL147657A0 (en) * 1999-07-15 2002-08-14 Res Dev Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof

Also Published As

Publication number Publication date
CA2422309A1 (en) 2003-09-29
MXPA03002865A (es) 2004-08-11
KR20030078803A (ko) 2003-10-08
AR039212A1 (es) 2005-02-09
BR0303080A (pt) 2004-02-17
US20030194734A1 (en) 2003-10-16
EP1349104A2 (en) 2003-10-01
EP1349104A3 (en) 2004-01-02
US20100009371A1 (en) 2010-01-14
CN1495272A (zh) 2004-05-12
JP2004163388A (ja) 2004-06-10

Similar Documents

Publication Publication Date Title
CN100577813C (zh) 肿瘤诊断组合物
US20030194734A1 (en) Selection of markers
AU2003203557B2 (en) Breast cancer prognostic portfolio
US6673545B2 (en) Prostate cancer markers
US20040146907A1 (en) Methods and compositions for detecting dysplasia
US20040241725A1 (en) Lung cancer detection
CA2430981A1 (en) Gene expression profiling of primary breast carcinomas using arrays of candidate genes
BRPI0708534A2 (pt) ensaio molecular para prognosticar a recorrência de cáncer do cólon dukes b
AU2006203169A1 (en) Predicting bone relapse of breast cancer
BRPI0616090A2 (pt) métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida
KR20040088384A (ko) 결장 직장암의 예후 진단법
CA2403946A1 (en) Genes expressed in foam cell differentiation
AU2008203227A1 (en) Colorectal cancer prognostics
KR20070090110A (ko) 위 암종으로부터의 림프절 전이의 검출법
CN100516233C (zh) 评估结肠直肠癌
KR101128112B1 (ko) 결장 직장암의 예후 진단법
HK1141054A (en) Tumor diagnostic composition
JP2003325191A (ja) 結腸直腸癌の評価
CN1890385A (zh) 结肠直肠癌相关基因
CN101405406A (zh) 诊断胰癌的方法
CA3067730C (en) Methods for detection of plasma cell dyscrasia
WO2013059152A2 (en) Methods and kits for selection of a treatment for breast cancer
CA3067730A1 (en) Methods for detection of plasma cell dyscrasia
MXPA04008401A (en) Colorectal cancer prognostics

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application